Biotech Values

[DewDiligence]

>VRTX – Do you think they are hearing footsteps and/or not as confident as they once were in their lead PI?<

Perhaps. Regardless of what happens with Telaprevir in the next few years, it’s clear that the long-term answer for HCV is not a drug that has to be taken every eight hours in order to preclude the rapid development of resistance. So it makes sense for VRTX to be aggressive in developing follow-up compounds.